- Home
- NTRB vs CNTB Comparison
NTRB vs CNTB Comparison
Compare NTRB & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- CNTB
- Stock Information
- Founded
- NTRB 2016
- CNTB 2012
- Country
- NTRB United States
- CNTB United States
- Employees
- NTRB N/A
- CNTB N/A
- Industry
- NTRB Industrial Specialties
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- CNTB Health Care
- Exchange
- NTRB Nasdaq
- CNTB Nasdaq
- Market Cap
- NTRB 77.9M
- CNTB 68.5M
- IPO Year
- NTRB N/A
- CNTB 2021
- Fundamental
- Price
- NTRB $6.17
- CNTB $1.17
- Analyst Decision
- NTRB
- CNTB Strong Buy
- Analyst Count
- NTRB 0
- CNTB 1
- Target Price
- NTRB N/A
- CNTB $8.00
- AVG Volume (30 Days)
- NTRB 28.2K
- CNTB 24.6K
- Earning Date
- NTRB 12-11-2024
- CNTB 09-05-2024
- Dividend Yield
- NTRB N/A
- CNTB N/A
- EPS Growth
- NTRB N/A
- CNTB N/A
- EPS
- NTRB N/A
- CNTB N/A
- Revenue
- NTRB $1,803,816.00
- CNTB $24,116,000.00
- Revenue This Year
- NTRB N/A
- CNTB N/A
- Revenue Next Year
- NTRB N/A
- CNTB $63.90
- P/E Ratio
- NTRB N/A
- CNTB N/A
- Revenue Growth
- NTRB N/A
- CNTB N/A
- 52 Week Low
- NTRB $1.93
- CNTB $0.68
- 52 Week High
- NTRB $9.60
- CNTB $2.84
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- CNTB 44.02
- Support Level
- NTRB $5.24
- CNTB $1.18
- Resistance Level
- NTRB $6.40
- CNTB $1.26
- Average True Range (ATR)
- NTRB 0.71
- CNTB 0.07
- MACD
- NTRB -0.12
- CNTB -0.01
- Stochastic Oscillator
- NTRB 33.23
- CNTB 13.59
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.